Q1 2024 · 13F-HR
Deep Track Capital, LPholdings as filed
Filed 2024-05-15 · accession 0001856083-24-000002
$3.49B
Reported value
66
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $171.3M | 4.91% | 3,479,853 | Common | SOLE |
| 031162100 | AMGN | AMGEN INC | $156.4M | 4.48% | 550,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $154.4M | 4.42% | 2,323,456 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $129.8M | 3.72% | 4,783,679 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $129.3M | 3.70% | 4,555,383 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $124.4M | 3.56% | 832,310 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $123.8M | 3.55% | 6,000,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $118.1M | 3.38% | 300,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $115.8M | 3.32% | 4,210,784 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $115.8M | 3.32% | 12,721,460 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $113.4M | 3.25% | 9,141,660 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $104.1M | 2.98% | 1,304,721 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $103.8M | 2.97% | 1,500,000 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $100.7M | 2.88% | 30,505,929 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $97.4M | 2.79% | 15,272,172 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $96.7M | 2.77% | 3,034,453 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $94.7M | 2.71% | 3,500,000 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $86.9M | 2.49% | 3,490,506 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $85.7M | 2.45% | 5,750,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $62.7M | 1.80% | 6,666,667 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $61.5M | 1.76% | 4,297,438 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $60.5M | 1.73% | 3,456,053 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $59.5M | 1.71% | 1,373,475 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $58.8M | 1.68% | 1,000,000 | Common | SOLE |
| 00182C103 | ANIP | ANI PHARMACEUTICALS INC | $56.8M | 1.63% | 822,001 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $56.8M | 1.63% | 7,370,000 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $51.3M | 1.47% | 3,187,415 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $50.7M | 1.45% | 1,262,246 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $48.6M | 1.39% | 10,953,937 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $46.0M | 1.32% | 1,213,420 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $44.1M | 1.26% | 2,997,830 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $42.8M | 1.23% | 2,572,460 | Common | SOLE |
| 28106W103 | EDIT | EDITAS MEDICINE INC | $41.0M | 1.17% | 5,527,290 | Common | SOLE |
| 31189P102 | FATE | FATE THERAPEUTICS INC | $40.9M | 1.17% | 5,572,607 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $40.0M | 1.15% | 6,100,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $38.1M | 1.09% | 2,250,000 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $36.5M | 1.05% | 1,595,400 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $36.5M | 1.05% | 3,225,419 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $35.5M | 1.02% | 1,643,881 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $26.3M | 0.75% | 7,000,000 | Common | SOLE |
| 23256X100 | — | CYBIN INC | $24.0M | 0.69% | 58,139,535 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $22.7M | 0.65% | 3,769,386 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $20.6M | 0.59% | 274,512 | Common | SOLE |
| 00847G705 | AGENEUR | AGENUS INC | $18.4M | 0.53% | 31,697,539 | Common | SOLE |
| 747324101 | PYXS | PYXIS ONCOLOGY INC | $17.8M | 0.51% | 4,184,100 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $17.2M | 0.49% | 18,400,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $15.9M | 0.46% | 493,352 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $13.8M | 0.39% | 1,000,000 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $12.6M | 0.36% | 2,684,344 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $12.1M | 0.35% | 175,400 | PUT | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $12.1M | 0.35% | 680,000 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $11.9M | 0.34% | 529,452 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $9.4M | 0.27% | 3,266,566 | Common | SOLE |
| 02157Q109 | ANRO | ALTO NEUROSCIENCE INC | $9.2M | 0.26% | 600,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $7.8M | 0.22% | 167,784 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $6.5M | 0.19% | 2,523,000 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $6.3M | 0.18% | 5,000,000 | Common | SOLE |
| 01626L105 | — | ALIGOS THERAPEUTICS INC | $6.0M | 0.17% | 6,102,770 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $5.8M | 0.17% | 1,240,034 | Common | SOLE |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $5.4M | 0.16% | 1,594,931 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $4.9M | 0.14% | 466,232 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $4.4M | 0.13% | 828,485 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $2.6M | 0.07% | 579,674 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $2.1M | 0.06% | 303,716 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $2.1M | 0.06% | 316,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $1.7M | 0.05% | 40,137 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.